Skip to Content

Advaxis Inc - Stock Quote ADXS

Rating as of

Morningstar's Advaxis Inc Stock Analysis

There is no Morningtar’s Analysis data available.

Advaxis Inc's Company Profile

Business Description

Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.

9 Deer Park Drive, Suite K-1
Monmouth Junction, NJ, 8540
T +1 609 452-9813
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jan 31, 2022
Fiscal Year End Oct 31, 2022
Stock Type Slow Growth
Employees 15